VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...
Brandon Arbini from California went to the doctor with mild stomach pain. His GI doctor scheduled a colonoscopy to ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...
Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide. Researchers have reported on the isolation ...
PROSTATE cancer diagnosis surged by a quarter in 2022 thanks to a Covid catch-up campaign as the total for all types of ...
Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...
LOS ANGELES – Oct. 15, 2024 – Stand Up To Cancer® (SU2C) today announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback